bpc-157 localized injection near injury site Dosing (Common Protocols), 🔹 Oral / Subcutaneous, • 500 mcg daily, • Duration: 6 weeks, 🔹 Intramuscular / Peritendinous, • 1 mg daily, • Duration: 6 weeks, ⚠️ Note:, Not approved by FDA or BPC-157 for Shoulder Injuries: Dosing

However, the problems associated with methaemoglobin formation, as described above for nitrites, apply to 4-DMAP to an even greater extent

I tried increasing the frequency of SI from 2 weekly to 1 weekly and the flushing got much worse - so I think this is the likely culprit

The answer depends on the patients diagnosis, goals, risk factors, medication history, sports rules, available evidence, and whether a medically supervised plan is appropriate

This multidisciplinary research profile has established BPC-157 as a recognised research peptide within experimental biology

Per CMS NCCI Policy Manual Chapter IV effective January 1, 2026, the same-joint arthroscopy bundling restriction for CPT codes 20600 through 20611 is an absolute restriction with no modifier override